# US 2006/0040856 A1 · Glycopegylated factor IX

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040856 A1
- Document ID: US20060040856A1
- Status: Published application
- Kind: A1
- Application number: 11/166,028
- Filed: 2005-06-23
- Published: 2006-02-23
- Earliest claimed: 2003-12-03
- Assignees: Neose Technologies, Inc.
- Inventors: Shawn DeFrees; Robert Bayer; Caryn Bowe; Krishnasamy Panneerselvam
- Web page: https://patentgrep.com/patent/US20060040856A1

## CPC

- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.

## Claims

### Claim 1

A Factor IX peptide conjugate comprising a glycosyl linking group attached to an amino acid residue of said peptide, said glycosyl linking group comprising a modified sialyl residue having the formula:
wherein
R2 is H, CH2OR7, COOR7 or OR7
wherein
R7 represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl;
R3 and R4 are members independently selected from H, substituted or unsubstituted alkyl, OR8, NHC(O)R9
wherein
R8 and R9 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl or sialic acid;
La is a linker selected from a bond, substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl′
R16 and R17 are independently selected polymeric arms;
X2 and X4 are independently selected linkage fragments joining polymeric moieties R16 and R17 to C; and
X5 is a non-reactive group.

### Claim 2 (depends on 1)

The peptide conjugate according to claim 1, wherein the moiety:
has a formula that is a member selected from:
wherein
Q is selected from H and substituted or unsubstituted C1-C6 alkyl;
e and f are integers independently selected from 1 to 2500; and
q is an integer from 0 to 20.

### Claim 3 (depends on 2)

The peptide conjugate according to claim 2, wherein said moiety has a formula that is a member selected from:
wherein
Q is selected from H and substituted or unsubstituted C1-C6 alkyl;
e, f and f′ are integers independently selected from 1 to 2500; and
q and q′ are integers independently selected from 1 to 20.

### Claim 4 (depends on 1)

The peptide conjugate according to claim 1, wherein said glycosyl linking group has a formula selected from:

### Claim 5 (depends on 4)

The peptide conjugate according to claim 4, wherein said glycosyl linking group has the formula:

### Claim 6 (depends on 5)

The peptide conjugate according to claim 5, wherein said glycosyl linking group attached to said amino acid residue has the formula:
wherein
AA is said amino acid residue of said peptide.

### Claim 7 (depends on 6)

The peptide conjugate according to claim 6, wherein said amino acid residue is a member selected from serine or threonine.

### Claim 8 (depends on 1)

The peptide conjugate according to claim 1, wherein said peptide has the amino acid sequence of SEQ. ID. NO: 1.

### Claim 9 (depends on 8)

The peptide according to claim 8, wherein said amino acid residue is a serine at position 61 of SEQ. ID. NO: 1.

### Claim 10 (depends on 1)

The peptide conjugate according to claim 1, wherein said peptide comprises at least one glycosyl linking group comprising a substructure having the formula:
wherein
R15 is said modified sialyl residue; and
p is an integer from 1 to 10.

### Claim 11 (depends on 10)

The peptide conjugate according to claim 10, wherein said at least one glycosyl linking group attached to an amino acid of said peptide has a formula selected from:
and combinations thereof
wherein
AA is said amino acid residue of said peptide;
t is an integer equal to 0 or 1;
p is an integer from 1 to 10; and
R15′ is a member selected from H, OH, sialic acid, said modified sialyl residue and Sia-Siap
wherein
Siap is said modified sialyl residue,
wherein at least one R15′ is selected from said modified sialyl residue and Sia-Siap.

### Claim 12 (depends on 11)

The peptide conjugate according to claim 11, wherein said amino acid residue is an asparagine residue.

### Claim 13 (depends on 12)

The peptide conjugate according to claim 12, wherein said peptide has the amino acid sequence of SEQ ID NO: 1.

### Claim 14 (depends on 13)

The peptide conjugate according to claim 13, wherein said glycosyl residue is attached to a member selected from Asn 157, Asn 167 and combinations thereof.

### Claim 15 (depends on 1)

A method of preparing a peptide conjugate according to claim 1, said method comprising:
(a) contacting a substrate Factor IX peptide comprising a glycosyl moiety selected from:
with a PEG-sialic acid donor having the formula:
wherein
c is 0 or 1; and
(b) contacting said Factor IX and said PEG-sialic acid donor with an enzyme that transfers PEG-sialic acid from said donor onto said glycosyl moiety, under conditions appropriate for said transfer.

### Claim 16 (depends on 15)

The method of claim 15, further comprising, prior to step (a):
(b) expressing said substrate Factor IX peptide in a suitable host.

### Claim 17 (depends on 16)

The method of claim 16, wherein said host is selected from an insect cell and a mammalian cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein said insect cell is a Spodoptera frugiperda cell line.

### Claim 19 (depends on 1)

A method of stimulating blood coagulation in a mammal, said method comprising administering to said mammal a peptide conjugate according to claim 1 in an amount sufficient to stimulate said blood coagulation.

### Claim 20 (depends on 1)

A method of treating hemophilia in a subject, said method comprising administering to said subject a peptide conjugate according to claim 1 in an amount effective to treat said hemophilia.

### Claim 21 (depends on 1)

A pharmaceutical formulation comprising the Factor IX peptide conjugate according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 22

A Factor IX peptide conjugate comprising a glycosyl linking group attached to an amino acid residue of said peptide, said glycosyl linking group comprising a modified sialyl residue having the formula:
wherein
R2 is H, CH2OR7, COOR7, COO− or OR7
wherein
R7 represents H, substituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl;
R3 and R4 are members independently selected from H, substituted or unsubstituted alkyl, OR8, NHC(O)R9
wherein
R8 and R9 are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl or sialic acid;
s is an integer from 1 to 20;
f is an integer from 1 to 2500; and
Q is a member selected from H and substituted or unsubstituted C1-C6 alkyl.

### Claim 23 (depends on 22)

The peptide conjugate according to claim 22, wherein said modified sialyl residue has the formula:

### Claim 24 (depends on 23)

The peptide conjugate according to claim 23, wherein Q is selected from H and CH3.

### Claim 25 (depends on 22)

The peptide conjugate according to claim 22, wherein said peptide comprises at least one glycosyl linking group comprising a substructure having the formula:
wherein
R15 is said modified sialyl residue; and
p is an integer from 1 to 10.

### Claim 26 (depends on 25)

The peptide conjugate according to claim 25, wherein said at least one glycosyl linking group attached to an amino acid of said peptide has a formula selected from:
and combinations thereof
wherein
AA is said amino acid residue of said peptide;
t is an integer equal to 0 or 1;
p is an integer from 1 to 10; and
R15′ is a member selected from H, OH, sialic acid, said modified sialyl residue and Sia-Siap
wherein
Siap is said modified sialyl residue,
wherein at least one R15′ is selected from said modified sialyl residue and Sia-Siap.

### Claim 27 (depends on 22)

The peptide conjugate according to claim 22, wherein said amino acid residue is asparagine.

### Claim 28 (depends on 27)

The peptide conjugate according to claim 27, wherein said peptide has the amino acid sequence of SEQ ID NO: 1.

### Claim 29 (depends on 28)

The peptide conjugate according to claim 28, wherein said glycosyl residue is attached to a member selected from Asn 157, Asn 167 and combinations thereof.

### Claim 30 (depends on 22)

The peptide conjugate according to claim 22, wherein said glycosyl linking group comprises the formula:
in which
b is 0 or 1.

### Claim 31 (depends on 30)

The peptide conjugate according to claim 30, wherein s is 1; and f is an integer from about 200 to about 300.

### Claim 32 (depends on 22)

The peptide conjugate according to claim 22, wherein said amino acid residue is a member selected from serine or threonine.

### Claim 33 (depends on 32)

The peptide conjugate according to claim 32, wherein said peptide has the amino acid sequence of SEQ. ID. NO: 1.

### Claim 34 (depends on 33)

The peptide conjugate according to claim 33, wherein said amino acid residue is a serine at position 61 of SEQ. ID. NO: 1.

### Claim 35 (depends on 22)

A method of preparing the peptide conjugate according to claim 22, said method comprising:
(a) contacting a substrate Factor IX peptide comprising a glycosyl moiety selected from:
with a PEG-sialic acid donor having the formula:
wherein
c is 0 or 1;
r is 0 or 1; and
(b) contacting Factor IX and said PEG-sialic acid donor with an enzyme that transfers PEG-sialic acid from said donor onto said glycosyl moiety, under conditions appropriate for said transfer.

### Claim 36 (depends on 35)

The method of claim 35, further comprising, prior to step (a):
(b) expressing said substrate Factor IX peptide in a suitable host.

### Claim 37 (depends on 36)

The method of claim 36, wherein said host an insect cell.

### Claim 38 (depends on 37)

The method of claim 37, wherein said insect cell is a Spodoptera frugiperda cell line.

### Claim 39 (depends on 22)

A method of stimulating blood coagulation in a mammal, said method comprising administering to said mammal a peptide conjugate according to claim 22 in an amount sufficient to stimulate said blood coagulation.

### Claim 40 (depends on 22)

A method of treating hemophilia in a subject, said method comprising administering to said subject a peptide conjugate according to claim 22 in an amount effective to treat said hemophilia.

### Claim 41 (depends on 22)

A pharmaceutical formulation comprising the Factor IX peptide conjugate according to claim 22, and a pharmaceutically acceptable carrier.
